Finance Watch: A One-Time Treatment For Heart Disease? Verve Raises $58.5m To Give It A Try

 
• By Mandy Jackson

Private Company Edition: With academic muscle, Google cash and nanoparticles, and various CRISPR licenses, Verve will develop gene-editing therapies for coronary heart disease prevention. Also, Vividion raises an $82m series B and two Belgian companies bring in $77.8m in VC cash.

Finance Watch
Verve will use gene editing to prevent coronary heart disease.

More from Financing

More from Business